cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2638cardio-643Research ArticleОБЗОРЫREVIEWSАнемия и железодефицит у больных с хронической сердечной недостаточностьюAnaemia and iron deficiency in chronic heart failure patientsВатутинН. Т.VatutinN. T.

Prospekt Iljicha 16, Donetsk 83003

ТарадинГ. Г.TaradinG. G.

Prospekt Iljicha 16, Donetsk 83003

taradin@inbox.ruКанишеваИ. В.KanishevaI. V.ВенжегаВ. В.VenzhehaV. V.«ДонНМУ им. М. Горького» МЗ УкраиныУкраинаM. Gorky Donetsk National Medical University of the Ukraine Ministry of Health CareUkraine201924052019594S420Copyright © Kardiomag, 20192019KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/643

В представленном обзоре затронуты вопросы распространенности анемии и железодефицита (ЖД) при ХСН, их влияние на течение и прогноз этого состояния. Сформулировано определение анемии и ЖД на основе оценки различных лабораторных данных. В частности, обсуждается диагностическая значимость определения сывороточного железа, ферритина сыворотки крови, коэффициента насыщения трансферрина, общей железосвязывающей способности сыворотки крови и уровень растворимых рецепторов трансферрина. Подчеркивается важность определения уровня железа в костном мозге, хоть и являющегося «золотым стандартом» диагностики ЖД, но редко используемого в широкой клинической практике. Освещены патогенетические механизмы развития ЖД при ХСН, включая недостаток поступления железа, роль воспаления, эритропоэтина, РААС и влияние некоторых фармакологических препаратов. Описываются физиологические последствия ЖД и анемии, активация гемодинамических и негемодинамических компенсаторных механизмов, развивающихся в ответ на анемию и нередко усугубляющих течение ХСН. Особое внимание уделено современным подходам в лечении анемии и ЖД при ХСН, включая обсуждение эффективности и безопасности пероральных, внутривенно вводимых препаратов железа и стимуляторов гемопоэза.

Tis review focused on prevalence of anemia and iron defciency (ID) in CHF and their effect on the course and prognosis of this condition. Based on evaluation of numerous laboratory data defnitions of anemia and ID were suggested. Specifcally, a diagnostic value of measuring serum iron, serum ferritin, transferrin saturation, total iron-binding capacity, and concentration of soluble transferrin receptors was discussed. Te review highlighted the importance of measuring bone marrow iron, which is rarely used in everyday clinical practice even though this test is considered a «gold standard» of ID diagnosis. Te review provided an insight into pathogenetic mechanisms of ID in CHF including insufcient iron supply, role of inflammation, erythropoietin, RAS, and effects of some pharmacological therapies. Te authors described physiological consequences of ID and anemia, activation of hemodynamic and non-hemodynamic compensatory mechanisms, which develop in response to anemia and not infrequently aggravate CHF. Special atention was paid to current approaches to treatment of anemia and ID in CHF, including a discussion of efcacy and safety of oral and intravenous dosage forms of iron and hemopoiesis stimulators.

анемияжелезодефицитхроническая сердечная недостаточностьдиагностикаэритропоэтинферритинтрансферрингепсидинпатогенезпрогнозлечениеanemiairon defciencychronic heart failurediagnosticserythropoietinferritintransferrinhepcidinpathogenesisprognosistreatmentReferencesSavarese G, Division of Cardiology, Department of Medicine, Karolinska Insitutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, Lund LH, Division of Cardiology, Department of Medicine, Karolinska Insitutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. Global Public Health Burden of Heart Failure. Cardiac Failure Review. 2017,3(1):7. DOI: 10.15420/cfr.2016:25:2Savarese G, Division of Cardiology, Department of Medicine, Karolinska Insitutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, Lund LH, Division of Cardiology, Department of Medicine, Karolinska Insitutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden. Global Public Health Burden of Heart Failure. Cardiac Failure Review. 2017,3(1):7. DOI: 10.15420/cfr.2016:25:2Кардиология. Национальное руководство. Краткое издание. Под ред. Е. В. Шляхто. – 2-е изд., перераб. и доп. – М.: ГЭОТАР-Медиа, 2018. – 816 с. ISBN 978-5-9704-4387-3Shlyakhto E. V. Cardiology. National guidelines. Short edition. 2nd ed. – M.: GEOTAR-Media, 816 p. [Russian] ISBN 978-5-9704-4387-3Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement from the American Heart Association. Circulation: Heart Failure. 2013,6(3):606–19. DOI: 10.1161/HHF.0b013e318291329aHeidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement from the American Heart Association. Circulation: Heart Failure. 2013,6(3):606–19. DOI: 10.1161/HHF.0b013e318291329aLópez-Sendón J. Te heart failure epidemic. Medicographia. 2011,33(4):363–9. Av. at: htps://www.medicographia.com/2012/02/the-heart-failure-epidemic/.López-Sendón J. Te heart failure epidemic. Medicographia. 2011,33(4):363–9. Av. at: htps://www.medicographia.com/2012/02/the-heart-failure-epidemic/.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/ AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017,136(6):e137–61. DOI: 10.1161/CIR.0000000000000509Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/ AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017,136(6):e137–61. DOI: 10.1161/CIR.0000000000000509Sirbu O, Floria M, Dascalita P, Stoica A, Adascalitei P, Sorodoc V et al. Anemia in heart failure - from guidelines to controversies and challenges. Te Anatolian Journal of Cardiology. 2018,20(1):52–9. DOI: 10.14744/AnatolJCardiol.2018.08634Sirbu O, Floria M, Dascalita P, Stoica A, Adascalitei P, Sorodoc V et al. Anemia in heart failure - from guidelines to controversies and challenges. Te Anatolian Journal of Cardiology. 2018,20(1):52–9. DOI: 10.14744/AnatolJCardiol.2018.08634Cavusoglu Y, Altay H, Çetiner M, Güvenç TS, Temizhan A, Ural D et al. Iron defciency and anemia in heart failure. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. 2017,45(Suppl 2):1–38. DOI: 10.5543/tkda.2017.79584Cavusoglu Y, Altay H, Çetiner M, Güvenç TS, Temizhan A, Ural D et al. Iron defciency and anemia in heart failure. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. 2017,45(Suppl 2):1–38. DOI: 10.5543/tkda.2017.79584Ватутин Н. Т., Склянная Е. В., Кириенко Т. С. Анемии у больных с хронической сердечной недостаточностью. Украинский кардиологический журнал. 2004,3:111-6Vatutin N. T., Sklyannaya E. V., Kirienko Т. S. Anemia in patients with chronic heart failure. Ukrainian Cardiology Journal. 2004,3:111–6. [Russian]Westphal JG, Bekfani T, Schulze PC. What’s new in heart failure therapy 2018? Interactive CardioVascular and Toracic Surgery. 2018,27(6):921–30. DOI: 10.1093/icvts/ivy282Westphal JG, Bekfani T, Schulze PC. What’s new in heart failure therapy 2018? Interactive CardioVascular and Toracic Surgery. 2018,27(6):921–30. DOI: 10.1093/icvts/ivy282Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Te Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016,37(27):2129–200. DOI: 10.1093/eurheartj/ehw128Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Te Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016,37(27):2129–200. DOI: 10.1093/eurheartj/ehw128Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in Heart Failure. JACC: Heart Failure. 2018,6(3):201–8. DOI: 10.1016/j.jchf.2017.08.023Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in Heart Failure. JACC: Heart Failure. 2018,6(3):201–8. DOI: 10.1016/j.jchf.2017.08.023Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ et al. Anemia and Mortality in Heart Failure Patients. Journal of the American College of Cardiology. 2008,52(10):818–27. DOI: 10.1016/j.jacc.2008.04.061Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ et al. Anemia and Mortality in Heart Failure Patients. Journal of the American College of Cardiology. 2008,52(10):818–27. DOI: 10.1016/j.jacc.2008.04.061Anand IS, Gupta P. Anemia and Iron Defciency in Heart Failure: Current Concepts and Emerging Terapies. Circulation. 2018,138(1):80–98. DOI: 10.1161/CIRCULATIONAHA.118.030099Anand IS, Gupta P. Anemia and Iron Defciency in Heart Failure: Current Concepts and Emerging Terapies. Circulation. 2018,138(1):80–98. DOI: 10.1161/CIRCULATIONAHA.118.030099Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al. Iron defciency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal. 2010,31(15):1872– 80. DOI: 10.1093/eurheartj/ehq158Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al. Iron defciency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal. 2010,31(15):1872– 80. DOI: 10.1093/eurheartj/ehq158Von Haehling S, Anker MS, Jankowska EA, Ponikowski P, Anker SD. Anemia in chronic heart failure: Can we treat? What to treat? Heart Failure Reviews. 2012,17(2):203–10. DOI: 10.1007/s10741-011-9283-xVon Haehling S, Anker MS, Jankowska EA, Ponikowski P, Anker SD. Anemia in chronic heart failure: Can we treat? What to treat? Heart Failure Reviews. 2012,17(2):203–10. DOI: 10.1007/s10741-011-9283-xPalazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M et al. Effects of β-erythropoietin treatment on lef ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. American Heart Journal. 2007,154(4):645.e9-645.e15. DOI: 10.1016/j.ahj.2007.07.022Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M et al. Effects of β-erythropoietin treatment on lef ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. American Heart Journal. 2007,154(4):645.e9-645.e15. DOI: 10.1016/j.ahj.2007.07.022World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1). Av. at: htps://www.who.int/vmnis/indicators/haemoglobin.pdf.World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 (WHO/NMH/NHD/MNM/11.1). Av. at: htps://www.who.int/vmnis/indicators/haemoglobin.pdf.Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A et al. Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients with Chronic Heart Failure: Results From Val-HeFT. Circulation. 2005,112(8):1121–7. DOI: 10.1161/CIRCULATIONAHA.104.512988Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A et al. Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients with Chronic Heart Failure: Results From Val-HeFT. Circulation. 2005,112(8):1121–7. DOI: 10.1161/CIRCULATIONAHA.104.512988Tang WHW, Yeo PSD. Epidemiology of Anemia in Heart Failure. Heart Failure Clinics. 2010,6(3):271–8. DOI: 10.1016/j.hfc.2010.03.007Tang WHW, Yeo PSD. Epidemiology of Anemia in Heart Failure. Heart Failure Clinics. 2010,6(3):271–8. DOI: 10.1016/j.hfc.2010.03.007World Health Organization. Iron defciency anaemia. Assessment, prevention and control. A guide for programme managers. Av. at: htps://www.who.int/nutrition/publications/fr/ida_assessment_prevention_control.pdf.World Health Organization. Iron defciency anaemia. Assessment, prevention and control. A guide for programme managers. Av. at: htps://www.who.int/nutrition/publications/fr/ida_assessment_prevention_control.pdf.Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS et al. Iron defciency across chronic inflammatory conditions: International expert opinion on defnition, diagnosis, and management. American Journal of Hematology. 2017,92(10):1068–78. DOI: 10.1002/ajh.24820Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS et al. Iron defciency across chronic inflammatory conditions: International expert opinion on defnition, diagnosis, and management. American Journal of Hematology. 2017,92(10):1068–78. DOI: 10.1002/ajh.24820Adams KF, Paterson JH, Oren RM, Mehra MR, O’Connor CM, Piña IL et al. Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. American Heart Journal. 2009,157(5):926–32. DOI: 10.1016/j.ahj.2009.01.012Adams KF, Paterson JH, Oren RM, Mehra MR, O’Connor CM, Piña IL et al. Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. American Heart Journal. 2009,157(5):926–32. DOI: 10.1016/j.ahj.2009.01.012Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A et al. Te impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. European Heart Journal. 2006,27(12):1440–6. DOI: 10.1093/eurheartj/ehl012Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A et al. Te impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. European Heart Journal. 2006,27(12):1440–6. DOI: 10.1093/eurheartj/ehl012Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM et al. Anemia and Outcomes in Patients with Heart Failure: A Study From the National Heart Care Project. Archives of Internal Medicine. 2005,165(19):2237–44. DOI: 10.1001/archinte.165.19.2237Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM et al. Anemia and Outcomes in Patients with Heart Failure: A Study From the National Heart Care Project. Archives of Internal Medicine. 2005,165(19):2237–44. DOI: 10.1001/archinte.165.19.2237Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. European Heart Journal. 2005,26(21):2232–7. DOI: 10.1093/eurheartj/ehi388Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. European Heart Journal. 2005,26(21):2232–7. DOI: 10.1093/eurheartj/ehi388Klip IjT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W et al. Iron defciency in chronic heart failure: An international pooled analysis. American Heart Journal. 2013,165(4):575-582.e3. DOI: 10.1016/j.ahj.2013.01.017Klip IjT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W et al. Iron defciency in chronic heart failure: An international pooled analysis. American Heart Journal. 2013,165(4):575-582.e3. DOI: 10.1016/j.ahj.2013.01.017Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with lef ventricular dysfunction. Journal of the American College of Cardiology. 2005,45(3):391–9. DOI: 10.1016/j.jacc.2004.10.038Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with lef ventricular dysfunction. Journal of the American College of Cardiology. 2005,45(3):391–9. DOI: 10.1016/j.jacc.2004.10.038Androne A-S, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003,107(2):226–9. PMID: 12538419Androne A-S, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003,107(2):226–9. PMID: 12538419Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al. Iron Defciency Predicts Impaired Exercise Capacity in Patients with Systolic Chronic Heart Failure. Journal of Cardiac Failure. 2011,17(11):899–906. DOI: 10.1016/j.cardfail.2011.08.003Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B et al. Iron Defciency Predicts Impaired Exercise Capacity in Patients with Systolic Chronic Heart Failure. Journal of Cardiac Failure. 2011,17(11):899–906. DOI: 10.1016/j.cardfail.2011.08.003Tkaczyszyn M, Comín-Colet J, Voors AA, van Veldhuisen DJ, Enjuanes C, Moliner-Borja P et al. Iron defciency and red cell indices in patients with heart failure: Iron defciency and red cell indices in heart failure. European Journal of Heart Failure. 2018,20(1):114–22. DOI: 10.1002/ejhf.820Tkaczyszyn M, Comín-Colet J, Voors AA, van Veldhuisen DJ, Enjuanes C, Moliner-Borja P et al. Iron defciency and red cell indices in patients with heart failure: Iron defciency and red cell indices in heart failure. European Journal of Heart Failure. 2018,20(1):114–22. DOI: 10.1002/ejhf.820Van Aelst LNL, Abraham M, Sadoune M, Lefebvre T, Manivet P, Logeart D et al. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up: Iron in AHF and CHF. European Journal of Heart Failure. 2017,19(8):1075–6. DOI: 10.1002/ejhf.837Van Aelst LNL, Abraham M, Sadoune M, Lefebvre T, Manivet P, Logeart D et al. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up: Iron in AHF and CHF. European Journal of Heart Failure. 2017,19(8):1075–6. DOI: 10.1002/ejhf.837Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet J-P, Hanon O et al. High prevalence of iron defciency in patients with acute decompensated heart failure. European Journal of Heart Failure. 2014,16(9):984–91. DOI: 10.1002/ejhf.139Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet J-P, Hanon O et al. High prevalence of iron defciency in patients with acute decompensated heart failure. European Journal of Heart Failure. 2014,16(9):984–91. DOI: 10.1002/ejhf.139Wong CCY, Ng ACC, Kritharides L, Sindone AP. Iron Defciency in Heart Failure: Looking Beyond Anaemia. Heart, Lung and Circulation. 2016,25(3):209–16. DOI: 10.1016/j.hlc.2015.06.827Wong CCY, Ng ACC, Kritharides L, Sindone AP. Iron Defciency in Heart Failure: Looking Beyond Anaemia. Heart, Lung and Circulation. 2016,25(3):209–16. DOI: 10.1016/j.hlc.2015.06.827Stewart Coats AJ. Intravenous ferric carboxymaltose for heart failure with iron defciency: Editorial comment. European Journal of Heart Failure. 2018,20(1):134–5. DOI: 10.1002/ejhf.1027Stewart Coats AJ. Intravenous ferric carboxymaltose for heart failure with iron defciency: Editorial comment. European Journal of Heart Failure. 2018,20(1):134–5. DOI: 10.1002/ejhf.1027Lam CSP, Doehner W, Comin-Colet J, on behalf of the IRON CORE Group. Iron defciency in chronic heart failure: case-based practical guidance: Iron defciency in CHF: case and practical guidance. ESC Heart Failure. 2018,5(5):764–71. DOI: 10.1002/ehf2.12333Lam CSP, Doehner W, Comin-Colet J, on behalf of the IRON CORE Group. Iron defciency in chronic heart failure: case-based practical guidance: Iron defciency in CHF: case and practical guidance. ESC Heart Failure. 2018,5(5):764–71. DOI: 10.1002/ehf2.12333Von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron defciency and cardiovascular disease. Nature Reviews Cardiology. 2015,12(11):659–69. DOI: 10.1038/nrcardio.2015.109Von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron defciency and cardiovascular disease. Nature Reviews Cardiology. 2015,12(11):659–69. DOI: 10.1038/nrcardio.2015.109Infusino I, Braga F, Dolci A, Panteghini M. Soluble Transferrin Receptor (sTf R) and sTf R/log Ferritin Index for the Diagnosis of Iron-Defciency Anemia A Meta-Analysis. American Journal of Clinical Pathology. 2012,138(5):642–9. DOI: 10.1309/AJCP16NTXZLZFAIBInfusino I, Braga F, Dolci A, Panteghini M. Soluble Transferrin Receptor (sTf R) and sTf R/log Ferritin Index for the Diagnosis of Iron-Defciency Anemia A Meta-Analysis. American Journal of Clinical Pathology. 2012,138(5):642–9. DOI: 10.1309/AJCP16NTXZLZFAIBWish JB. Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation. Clinical Journal of the American Society of Nephrology. 2006,1(Supplement 1):S4–8. DOI: 10.2215/CJN.01490506Wish JB. Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation. Clinical Journal of the American Society of Nephrology. 2006,1(Supplement 1):S4–8. DOI: 10.2215/CJN.01490506Андреичев Н. А., Балеева Л. В. Железодефицитные состояния и железодефицитная анемия. Вестник современной клинической медицины. 2009,2(3):60-5Andreichev N. A., Baleeva L. V. Iron defciency and iron defciency anemia. Te Bulletin of Contemporary Clinical Medicine. 2009,2(3):60– 5. [Russian]Rehu M, Ahonen S, Punnonen K. Te diagnostic accuracy of the percentage of hypochromic red blood cells (%HYPOm) and cellular hemoglobin in reticulocytes (CHr) in differentiating iron defciency anemia and anemia of chronic diseases. Clinica Chimica Acta. 2011,412(19– 20):1809–13. DOI: 10.1016/j.cca.2011.06.004Rehu M, Ahonen S, Punnonen K. Te diagnostic accuracy of the percentage of hypochromic red blood cells (%HYPOm) and cellular hemoglobin in reticulocytes (CHr) in differentiating iron defciency anemia and anemia of chronic diseases. Clinica Chimica Acta. 2011,412(19– 20):1809–13. DOI: 10.1016/j.cca.2011.06.004Grote Beverborg N, Klip IjT, Meijers WC, Voors AA, Vegter EL, van der Wal HH et al. Defnition of Iron Defciency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure. 2018,11(2):e004519. DOI: 10.1161/CIRCHEARTFAILURE.117.004519Grote Beverborg N, Klip IjT, Meijers WC, Voors AA, Vegter EL, van der Wal HH et al. Defnition of Iron Defciency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure. 2018,11(2):e004519. DOI: 10.1161/CIRCHEARTFAILURE.117.004519Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S et al. Iron status in patients with chronic heart failure. European Heart Journal. 2013,34(11):827–34. DOI: 10.1093/eurheartj/ehs377Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S et al. Iron status in patients with chronic heart failure. European Heart Journal. 2013,34(11):827–34. DOI: 10.1093/eurheartj/ehs377Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Беграмбекова Ю. Л., Васюк Ю. А., Гарганеева А. А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018,58(S6):8- 164. DOI: 10.18087/cardio.2475Mareev V. Yu., Fomin I. V., Ageev F. T., Begrambekova Yu. L., Vasyuk Yu. A., Garganeeva A. A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientifc Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018,58(S6):8–164. [Russian]. DOI: 10.18087/cardio.2475Musallam KM, Taher AT. Iron defciency beyond erythropoiesis: should we be concerned? Current Medical Research and Opinion. 2018,34(1):81–93. DOI: 10.1080/03007995.2017.1394833Musallam KM, Taher AT. Iron defciency beyond erythropoiesis: should we be concerned? Current Medical Research and Opinion. 2018,34(1):81–93. DOI: 10.1080/03007995.2017.1394833Jankowska EA, Wojtas K, Kasztura M, Mazur G, Butrym A, Kalicinska E et al. Bone marrow iron depletion is common in patients with coronary artery disease. International Journal of Cardiology. 2015,182:517–22. DOI: 10.1016/j.ijcard.2014.10.006Jankowska EA, Wojtas K, Kasztura M, Mazur G, Butrym A, Kalicinska E et al. Bone marrow iron depletion is common in patients with coronary artery disease. International Journal of Cardiology. 2015,182:517–22. DOI: 10.1016/j.ijcard.2014.10.006Выдыборец С. В. Сергиенко А. В., Попович Ю. Ю. Гепсидин – как центральный регулятор метаболизма железа. Украинский журнал гематологии и трансфузиологии. 2011,5(2):5-9Vydyborets S. V., Sergienko A. V., Popovich Yu. Yu. Hepcidin-as a Central regulator of iron metabolism. Ukrainian journal of Hematology and blood transfusion. 2011,5(2):5–9. [Russian]Левина А. А., Казюкова Т. В., Цветаева Н. Т., Сергеева А. И., Мамукова Ю. И., Романова Е. А. и др. Гепсидин, как регулятор гомеостаза железа. Педиатрия. Журнал имени Г. Н. Сперанского. 2008,87(1):11Levina A. A., Kazyukova T. V., Tsvetaeva N. V., Sergeeva A. I., Mamukova Yu. I., Romanova E. A. et al. Hepsidin as regulator of iron homeostasis. Pediatria. Journal named afer G.N.Speransky. 2008,87(1):11. [Russian]Nemeth E, Ganz T. Te Role of Hepcidin in Iron Metabolism. Acta Haematologica. 2009,122(2–3):78–86. DOI: 10.1159/000243791Nemeth E, Ganz T. Te Role of Hepcidin in Iron Metabolism. Acta Haematologica. 2009,122(2–3):78–86. DOI: 10.1159/000243791van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CMM, van Riel PLCM, van Ede AE et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron defciency in rheumatoid arthritis patients with anemia. Arthritis & Rheumatism. 2011,63(12):3672–80. DOI: 10.1002/art.30623van Santen S, van Dongen-Lases EC, de Vegt F, Laarakkers CMM, van Riel PLCM, van Ede AE et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron defciency in rheumatoid arthritis patients with anemia. Arthritis & Rheumatism. 2011,63(12):3672–80. DOI: 10.1002/art.30623Стуклов Н. И. Дефицит железа и анемия у больных хронической сердечной недостаточностью. Рациональная фармакотерапия в кардиологии. 2017,13(5):651-60. DOI: 10.20996/1819-6446-2017-13-5-651-660Stuklov N. I. Iron Defciency and Anemia in Patients with Chronic Heart Failure. Rational Pharmacotherapy in Cardiology. 2017,13(5):651–60. [Russian]. DOI: 10.20996/1819-6446-2017-13-5-651-660Kaldara E, Malliaras K, Barbarousi D, Kapelios CJ, Vakrou S, Tachliabouris I et al. A Novel Simple Diagnostic Algorithm for Rapid and Accurate Detection of Anemia Etiology in Patients With Advanced Heart Failure. Journal of Cardiac Failure. 2018,24(11):806–7. DOI: 10.1016/j.cardfail.2018.09.018Kaldara E, Malliaras K, Barbarousi D, Kapelios CJ, Vakrou S, Tachliabouris I et al. A Novel Simple Diagnostic Algorithm for Rapid and Accurate Detection of Anemia Etiology in Patients With Advanced Heart Failure. Journal of Cardiac Failure. 2018,24(11):806–7. DOI: 10.1016/j.cardfail.2018.09.018Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG et al. Etiology of anemia in patients with advanced heart failure. Journal of the American College of Cardiology. 2006,48(12):2485– 9. DOI: 10.1016/j.jacc.2006.08.034Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG et al. Etiology of anemia in patients with advanced heart failure. Journal of the American College of Cardiology. 2006,48(12):2485– 9. DOI: 10.1016/j.jacc.2006.08.034Hofrand AV, Moss PAH. Hofrand’s essential haematology. – Chichester, West Sussex , Hoboken, NJ: John Wiley & Sons, 27–40 p. ISBN 978-1-118-40867-4Hofrand AV, Moss PAH. Hofrand’s essential haematology. – Chichester, West Sussex , Hoboken, NJ: John Wiley & Sons, 27–40 p. ISBN 978-1-118-40867-4Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. International Journal of Hematology. 2018,107(1):16–30. DOI: 10.1007/s12185-017-2373-3Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. International Journal of Hematology. 2018,107(1):16–30. DOI: 10.1007/s12185-017-2373-3Chifman J, Laubenbacher R, Torti SV. A Systems Biology Approach to Iron Metabolism. In A Systems Biology Approach to Blood. t. 844. – NY:Springer New York, 2014. - P.201-25. ISBN: 978-1-4939- 2094-5. DOI: 10.1007/978-1-4939-2095-2_10. In: A Systems Biology Approach to Blood Corey SJ, Kimmel M, Leonard JN, editors -New York, NY: Springer New York,Chifman J, Laubenbacher R, Torti SV. A Systems Biology Approach to Iron Metabolism. In A Systems Biology Approach to Blood. t. 844. – NY:Springer New York, 2014. - P.201-25. ISBN: 978-1-4939- 2094-5. DOI: 10.1007/978-1-4939-2095-2_10. In: A Systems Biology Approach to Blood Corey SJ, Kimmel M, Leonard JN, editors -New York, NY: Springer New York,Волкова С. А., Боровков Н. Н. Основы клинической гематологии: учебное пособие. – Н. Новгород: Издательство НижГМА, 2013. - 400с. ISBN 978-5-7032-0882-3Volkova S. A., Borovkov N. N. Fundamentals of clinical Hematology: a training manual. -N. Novgorod: Publishing house of Nizhny Novgorod state medical Academy, 400 p. [Russian]. ISBN 978-5-7032-0882-3Cunha GJL, Rocha BML, Menezes Falcão L. Iron defciency in chronic and acute heart failure: A contemporary review on intertwined conditions. European Journal of Internal Medicine. 2018,52:1–7. DOI: 10.1016/j.ejim.2018.04.013Cunha GJL, Rocha BML, Menezes Falcão L. Iron defciency in chronic and acute heart failure: A contemporary review on intertwined conditions. European Journal of Internal Medicine. 2018,52:1–7. DOI: 10.1016/j.ejim.2018.04.013Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006,290(2):G199–203. DOI: 10.1152/ajpgi.00412.2005Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2006,290(2):G199–203. DOI: 10.1152/ajpgi.00412.2005Ponka P, Lok CN. Te transferrin receptor: role in health and disease. Te International Journal of Biochemistry & Cell Biology. 1999,31(10):1111–37. PMID: 10582342Ponka P, Lok CN. Te transferrin receptor: role in health and disease. Te International Journal of Biochemistry & Cell Biology. 1999,31(10):1111–37. PMID: 10582342Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Defciency. Gastroenterology. 2017,152(4):821-829.e1. DOI: 10.1053/j.gastro.2016.11.023Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Defciency. Gastroenterology. 2017,152(4):821-829.e1. DOI: 10.1053/j.gastro.2016.11.023Suominen P, Punnonen K, Rajamäki A, Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron defcits. Blood. 1998,92(8):2934–9. PMID: 9763580Suominen P, Punnonen K, Rajamäki A, Irjala K. Serum transferrin receptor and transferrin receptor-ferritin index identify healthy subjects with subclinical iron defcits. Blood. 1998,92(8):2934–9. PMID: 9763580Gunawardena S, Dunlap ME. Anemia and Iron Defciency in Heart Failure. Current Heart Failure Reports. 2012,9(4):319–27. DOI: 10.1007/s11897-012-0112-xGunawardena S, Dunlap ME. Anemia and Iron Defciency in Heart Failure. Current Heart Failure Reports. 2012,9(4):319–27. DOI: 10.1007/s11897-012-0112-xSilverberg D, Wexler D, Schwartz D. Is Correction of Iron Defciency a New Addition to the Treatment of the Heart Failure? International Journal of Molecular Sciences. 2015,16(12):14056–74. DOI: 10.3390/ijms160614056Silverberg D, Wexler D, Schwartz D. Is Correction of Iron Defciency a New Addition to the Treatment of the Heart Failure? International Journal of Molecular Sciences. 2015,16(12):14056–74. DOI: 10.3390/ijms160614056Соломахина Н. И., Находнова Е. С., Ершов В. И., Беленков Ю. Н. Роль гепсидина в формировании анемии хронических заболеваний и железодефицитной анемии у больных с хронической сердечной недостаточностью в пожилом и старческом возрасте. Кардиология. 2018,58(3):20–7. DOI: 10.18087/cardio.2018.3.10094Solomakhina N. I., Nakhodnova E. S., Ershov V. I., Belenkov Yu. N. Te Role of Hepcidin in Formation of Anemia of Chronic Disease and Iron Defciency Anemia in Elderly and Old Patients with Chronic Heart Failure. Kardiologiia. 2018,58(3):20–7. [Russian]. DOI: 10.18087/cardio.2018.3.10094Weiss G. Iron metabolism in the anemia of chronic disease. Biochimica et Biophysica Acta (BBA) - General Subjects. 2009,1790(7):682–93. DOI: 10.1016/j.bbagen.2008.08.006Weiss G. Iron metabolism in the anemia of chronic disease. Biochimica et Biophysica Acta (BBA) - General Subjects. 2009,1790(7):682–93. DOI: 10.1016/j.bbagen.2008.08.006Souma T, Suzuki N, Yamamoto M. Renal erythropoietin-producing cells in health and disease. Frontiers in Physiology. 2015,6:167. DOI: 10.3389/fphys.2015.00167Souma T, Suzuki N, Yamamoto M. Renal erythropoietin-producing cells in health and disease. Frontiers in Physiology. 2015,6:167. DOI: 10.3389/fphys.2015.00167Montero D, Haider T, Flammer AJ. Erythropoietin response to anaemia in heart failure. European Journal of Preventive Cardiology. 2019,26(1):7–17. DOI: 10.1177/2047487318790823Montero D, Haider T, Flammer AJ. Erythropoietin response to anaemia in heart failure. European Journal of Preventive Cardiology. 2019,26(1):7–17. DOI: 10.1177/2047487318790823Zahidova KK. Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia. Journal of Basic and Clinical Physiology and Pharmacology. 2018,29(1):11–7. DOI: 10.1515/jbcpp-2016-0102Zahidova KK. Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia. Journal of Basic and Clinical Physiology and Pharmacology. 2018,29(1):11–7. DOI: 10.1515/jbcpp-2016-0102George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T et al. Circulating Erythropoietin Levels and Prognosis in Patients with Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers. Archives of Internal Medicine. 2005,165(11):1304–9. DOI: 10.1001/archinte.165.11.1304George J, Patal S, Wexler D, Abashidze A, Shmilovich H, Barak T et al. Circulating Erythropoietin Levels and Prognosis in Patients with Congestive Heart Failure: Comparison With Neurohormonal and Inflammatory Markers. Archives of Internal Medicine. 2005,165(11):1304–9. DOI: 10.1001/archinte.165.11.1304Соломахина Н. И., Находнова Е. С., Беленков Ю. Н. Анемия хронических заболеваний и железодефицитная анемия: сравнительная характеристика показателей феррокинетики и их связь с воспалением у больных ХСН в пожилом и старческом возрасте. Кардиология. 2018,58(S8):58-64. DOI: 10.18087/cardio.2472Solomakhina N. I., Nakhodnova E. S., Belenkov Yu. N. Anemia of chronic disease and iron defciency anemia: Comparative characteristics of ferrokinetic parameters and their relationship with inflammation in late middle-aged and elderly patients with CHF. Kardiologiia. 2018,58(S8):58– 64. [Russian]. DOI: 10.18087/cardio.2472Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study: Biomarkers and adverse outcome in heart failure. European Journal of Heart Failure. 2018,20(2):268–77. DOI: 10.1002/ejhf.988Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study: Biomarkers and adverse outcome in heart failure. European Journal of Heart Failure. 2018,20(2):268–77. DOI: 10.1002/ejhf.988van der Meer P, Lipsic E, Westenbrink BD, van de Wal RMA, Schoemaker RG, Vellenga E et al. Levels of Hematopoiesis Inhibitor N-Acetyl-SerylAspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. Circulation. 2005,112(12):1743–7. DOI: 10.1161/CIRCULATIONAHA.105.549121van der Meer P, Lipsic E, Westenbrink BD, van de Wal RMA, Schoemaker RG, Vellenga E et al. Levels of Hematopoiesis Inhibitor N-Acetyl-SerylAspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. Circulation. 2005,112(12):1743–7. DOI: 10.1161/CIRCULATIONAHA.105.549121Nagatomo Y, Yoshikawa T, Okamoto H, Kitabatake A, Hori M, on behalf of J-CHF Investigators. Anemia Is Associated with Blunted Response to β-Blocker Terapy Using Carvedilol ― Insights From Japanese Chronic Heart Failure ( J-CHF) Study ―. Circulation Journal. 2018,82(3):691–8. DOI: 10.1253/circj.CJ-17-0442Nagatomo Y, Yoshikawa T, Okamoto H, Kitabatake A, Hori M, on behalf of J-CHF Investigators. Anemia Is Associated with Blunted Response to β-Blocker Terapy Using Carvedilol ― Insights From Japanese Chronic Heart Failure ( J-CHF) Study ―. Circulation Journal. 2018,82(3):691–8. DOI: 10.1253/circj.CJ-17-0442Westenbrink BD, Voors AA, de Boer R, Schuringa JJ, Klinkenberg T, van der Harst P et al. Bone marrow dysfunction in chronic heart failure patients. European Journal of Heart Failure. 2010,12(7):676–84. DOI: 10.1093/eurjhf/hfq061Westenbrink BD, Voors AA, de Boer R, Schuringa JJ, Klinkenberg T, van der Harst P et al. Bone marrow dysfunction in chronic heart failure patients. European Journal of Heart Failure. 2010,12(7):676–84. DOI: 10.1093/eurjhf/hfq061Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. British Heart Journal. 1993,70(4):357–62. PMID: 8217445Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. British Heart Journal. 1993,70(4):357–62. PMID: 8217445Ni Z, Morcos S, Vaziri ND. Up-regulation of renal and vascular nitric oxide synthase in iron-defciency anemia. Kidney International. 1997,52(1):195–201. PMID: 9211362Ni Z, Morcos S, Vaziri ND. Up-regulation of renal and vascular nitric oxide synthase in iron-defciency anemia. Kidney International. 1997,52(1):195–201. PMID: 9211362Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989,80(2):299–305. PMID: 2752558Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989,80(2):299–305. PMID: 2752558McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrology, Dialysis, Transplantation: Ofcial Publication of the European Dialysis and Transplant Association - European Renal Association. 2000,15(9):1425– 30. PMID: 10978402McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrology, Dialysis, Transplantation: Ofcial Publication of the European Dialysis and Transplant Association - European Renal Association. 2000,15(9):1425– 30. PMID: 10978402O’Meara E. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients with Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006,113(7):986–94. DOI: 10.1161/CIRCULATIONAHA.105.582577O’Meara E. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients with Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006,113(7):986–94. DOI: 10.1161/CIRCULATIONAHA.105.582577Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003,107(2):223–5. DOI: 10.1161/01.CIR.0000052622.51963.FCEzekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003,107(2):223–5. DOI: 10.1161/01.CIR.0000052622.51963.FCMartens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron defciency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiologica. 2018,73(2):115–23. DOI: 10.1080/00015385.2017.1351239Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron defciency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiologica. 2018,73(2):115–23. DOI: 10.1080/00015385.2017.1351239Kobak K, Radwańska M, Dzięgała M, Kasztura M, Josiak K, Banasiak W et al. Structural and functional abnormalities in iron-depleted heart. Heart Failure Reviews. 2019,24(2):269–77. DOI: 10.1007/s10741-018-9738-4Kobak K, Radwańska M, Dzięgała M, Kasztura M, Josiak K, Banasiak W et al. Structural and functional abnormalities in iron-depleted heart. Heart Failure Reviews. 2019,24(2):269–77. DOI: 10.1007/s10741-018-9738-4Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis: Iron and mitochondria in heart failure. European Journal of Heart Failure. 2017,19(4):522–30. DOI: 10.1002/ejhf.640Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H et al. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis: Iron and mitochondria in heart failure. European Journal of Heart Failure. 2017,19(4):522–30. DOI: 10.1002/ejhf.640Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzóska K, Piotrowski W et al. Myocardial iron homeostasis in advanced chronic heart failure patients. International Journal of Cardiology. 2012,159(1):47–52. DOI: 10.1016/j.ijcard.2011.08.006Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzóska K, Piotrowski W et al. Myocardial iron homeostasis in advanced chronic heart failure patients. International Journal of Cardiology. 2012,159(1):47–52. DOI: 10.1016/j.ijcard.2011.08.006Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG et al. Iron defciency impairs contractility of human cardiomyocytes through decreased mitochondrial function: Impaired contractility in iron-defcient cardiomyocytes. European Journal of Heart Failure. 2018,20(5):910–9. DOI: 10.1002/ejhf.1154Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG et al. Iron defciency impairs contractility of human cardiomyocytes through decreased mitochondrial function: Impaired contractility in iron-defcient cardiomyocytes. European Journal of Heart Failure. 2018,20(5):910–9. DOI: 10.1002/ejhf.1154Kasztura M, Dzięgała M, Kobak K, Bania J, Mazur G, Banasiak W et al. Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. Kardiologia Polska. 2017,75(3):267– 75. DOI: 10.5603/KP.a2016.0155Kasztura M, Dzięgała M, Kobak K, Bania J, Mazur G, Banasiak W et al. Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. Kardiologia Polska. 2017,75(3):267– 75. DOI: 10.5603/KP.a2016.0155Scrutinio D, Passantino A, Santoro D, Catanzaro R. Te cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. European Journal of Heart Failure. 2011,13(1):61–7. DOI: 10.1093/eurjhf/hfq167Scrutinio D, Passantino A, Santoro D, Catanzaro R. Te cardiorenal anaemia syndrome in systolic heart failure: prevalence, clinical correlates, and long-term survival. European Journal of Heart Failure. 2011,13(1):61–7. DOI: 10.1093/eurjhf/hfq167Núñez J, Sanchis J, Bayés-Genis A. Iron status measurement in routine heart failure assessment: a call for action: Editorial comment. European Journal of Heart Failure. 2018,20(1):123–4. DOI: 10.1002/ejhf.967Núñez J, Sanchis J, Bayés-Genis A. Iron status measurement in routine heart failure assessment: a call for action: Editorial comment. European Journal of Heart Failure. 2018,20(1):123–4. DOI: 10.1002/ejhf.967Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered Iron Homeostasis in Chronic Heart Failure. Journal of the American College of Cardiology. 2011,58(12):1241–51. DOI: 10.1016/j.jacc.2011.04.040Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered Iron Homeostasis in Chronic Heart Failure. Journal of the American College of Cardiology. 2011,58(12):1241–51. DOI: 10.1016/j.jacc.2011.04.040Wienbergen H, Pfster O, Hochadel M, Fach A, Backhaus T, Bruder O et al. Long-term effects of iron defciency in patients with heart failure with or without anemia: the RID-HF follow-up study. Clinical Research in Cardiology. 2019,108(1):93–100. DOI: 10.1007/s00392-018-1327-yWienbergen H, Pfster O, Hochadel M, Fach A, Backhaus T, Bruder O et al. Long-term effects of iron defciency in patients with heart failure with or without anemia: the RID-HF follow-up study. Clinical Research in Cardiology. 2019,108(1):93–100. DOI: 10.1007/s00392-018-1327-yParikh A, Natarajan S, Lipsitz SR, Katz SD. Iron Defciency in Community-Dwelling US Adults With Self-Reported Heart Failure in the National Health and Nutrition Examination Survey III: Prevalence and Associations With Anemia and Inflammation. Circulation: Heart Failure. 2011,4(5):599–606. DOI: 10.1161/CIRCHEARTFAILURE.111.960906Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron Defciency in Community-Dwelling US Adults With Self-Reported Heart Failure in the National Health and Nutrition Examination Survey III: Prevalence and Associations With Anemia and Inflammation. Circulation: Heart Failure. 2011,4(5):599–606. DOI: 10.1161/CIRCHEARTFAILURE.111.960906Núñez J, Comín-Colet J, Miñana G, Núñez E, Santas E, Mollar A et al. Iron defciency and risk of early readmission following a hospitalization for acute heart failure: Iron defciency and rehospitalization. European Journal of Heart Failure. 2016,18(7):798–802. DOI: 10.1002/ejhf.513Núñez J, Comín-Colet J, Miñana G, Núñez E, Santas E, Mollar A et al. Iron defciency and risk of early readmission following a hospitalization for acute heart failure: Iron defciency and rehospitalization. European Journal of Heart Failure. 2016,18(7):798–802. DOI: 10.1002/ejhf.513Niehaus ED, Malhotra R, Cocca-Spofford D, Semigran M, Lewis GD. Repletion of Iron Stores With the Use of Oral Iron Supplementation in Patients With Systolic Heart Failure. Journal of Cardiac Failure. 2015,21(8):694–7. DOI: 10.1016/j.cardfail.2015.05.006Niehaus ED, Malhotra R, Cocca-Spofford D, Semigran M, Lewis GD. Repletion of Iron Stores With the Use of Oral Iron Supplementation in Patients With Systolic Heart Failure. Journal of Cardiac Failure. 2015,21(8):694–7. DOI: 10.1016/j.cardfail.2015.05.006Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients with Heart Failure With Reduced Ejection Fraction and Iron Defciency: Te IRONOUT HF Randomized Clinical Trial. JAMA. 2017,317(19):1958–66. DOI: 10.1001/jama.2017.5427Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients with Heart Failure With Reduced Ejection Fraction and Iron Defciency: Te IRONOUT HF Randomized Clinical Trial. JAMA. 2017,317(19):1958–66. DOI: 10.1001/jama.2017.5427McDonagh T, Macdougall IC. Iron therapy for the treatment of iron defciency in chronic heart failure: intravenous or oral?: Iron therapy in heart failure: intravenous or oral? European Journal of Heart Failure. 2015,17(3):248–62. DOI: 10.1002/ejhf.236McDonagh T, Macdougall IC. Iron therapy for the treatment of iron defciency in chronic heart failure: intravenous or oral?: Iron therapy in heart failure: intravenous or oral? European Journal of Heart Failure. 2015,17(3):248–62. DOI: 10.1002/ejhf.236Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrology Dialysis Transplantation. 2010,25(11):3631–40. DOI: 10.1093/ndt/gfq260Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrology Dialysis Transplantation. 2010,25(11):3631–40. DOI: 10.1093/ndt/gfq260Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W et al. Effects of intravenous iron therapy in iron-defcient patients with systolic heart failure: a meta-analysis of randomized controlled trials: Intravenous iron therapy in systolic heart failure. European Journal of Heart Failure. 2016,18(7):786–95. DOI: 10.1002/ejhf.473Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W et al. Effects of intravenous iron therapy in iron-defcient patients with systolic heart failure: a meta-analysis of randomized controlled trials: Intravenous iron therapy in systolic heart failure. European Journal of Heart Failure. 2016,18(7):786–95. DOI: 10.1002/ejhf.473Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients with Symptomatic Chronic Heart Failure and Iron Defciency. Journal of the American College of Cardiology. 2008,51(2):103–12. DOI: 10.1016/j.jacc.2007.09.036Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M et al. Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients with Symptomatic Chronic Heart Failure and Iron Defciency. Journal of the American College of Cardiology. 2008,51(2):103–12. DOI: 10.1016/j.jacc.2007.09.036Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barreto AC, de Albuquerque D et al. IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology. 2013,168(4):3439–42. DOI: 10.1016/j.ijcard.2013.04.181Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barreto AC, de Albuquerque D et al. IRON-HF study: A randomized trial to assess the effects of iron in heart failure patients with anemia. International Journal of Cardiology. 2013,168(4):3439–42. DOI: 10.1016/j.ijcard.2013.04.181Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Defciency. New England Journal of Medicine. 2009,361(25):2436– 48. DOI: 10.1056/NEJMoa0908355Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Defciency. New England Journal of Medicine. 2009,361(25):2436– 48. DOI: 10.1056/NEJMoa0908355Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Benefcial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron defciency. European Heart Journal. 2015,36(11):657–68. DOI: 10.1093/eurheartj/ehu385Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Benefcial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron defciency. European Heart Journal. 2015,36(11):657–68. DOI: 10.1093/eurheartj/ehu385Altman NL, Patel A. Intravenous Iron Terapy in Heart Failure. Heart Failure Clinics. 2018,14(4):537–43. DOI: 10.1016/j.hfc.2018.06.003Altman NL, Patel A. Intravenous Iron Terapy in Heart Failure. Heart Failure Clinics. 2018,14(4):537–43. DOI: 10.1016/j.hfc.2018.06.003Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R et al. Intravenous ferric carboxymaltose in irondefcient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 2013,15(11):1267–76. DOI: 10.1093/eurjhf/hf099Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R et al. Intravenous ferric carboxymaltose in irondefcient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. European Journal of Heart Failure. 2013,15(11):1267–76. DOI: 10.1093/eurjhf/hf099Anker SD, Kirwan B-A, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-defcient heart failure patients: an individual patient data meta-analysis: Outcomes in iron-defcient heart failure patients. European Journal of Heart Failure. 2018,20(1):125–33. DOI: 10.1002/ejhf.823Anker SD, Kirwan B-A, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-defcient heart failure patients: an individual patient data meta-analysis: Outcomes in iron-defcient heart failure patients. European Journal of Heart Failure. 2018,20(1):125–33. DOI: 10.1002/ejhf.823Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T et al. Te impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study: Impact of i.v. ferric carboxymaltose on renal function. European Journal of Heart Failure. 2015,17(3):329–39. DOI: 10.1002/ejhf.229Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T et al. Te impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study: Impact of i.v. ferric carboxymaltose on renal function. European Journal of Heart Failure. 2015,17(3):329–39. DOI: 10.1002/ejhf.229Van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Defciency. Circulation. 2017,136(15):1374–83. DOI: 10.1161/CIRCULATIONAHA.117.027497Van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Defciency. Circulation. 2017,136(15):1374–83. DOI: 10.1161/CIRCULATIONAHA.117.027497Van der Wal HH, Comin-Colet J, Klip IT, Enjuanes C, Beverborg NG, Voors AA et al. Vitamin B12 and folate defciency in chronic heart failure. Heart. 2015,101(4):302–10. DOI: 10.1136/heartjnl-2014-306022Van der Wal HH, Comin-Colet J, Klip IT, Enjuanes C, Beverborg NG, Voors AA et al. Vitamin B12 and folate defciency in chronic heart failure. Heart. 2015,101(4):302–10. DOI: 10.1136/heartjnl-2014-306022Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015,1:CD006612. DOI: 10.1002/14651858.CD006612.pub4. In: Cochrane Database of Systematic Reviews the Cochrane Collaboration, editor -Chichester, UK: John Wiley & Sons, Ltd,Martí-Carvajal AJ, Solà I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015,1:CD006612. DOI: 10.1002/14651858.CD006612.pub4. In: Cochrane Database of Systematic Reviews the Cochrane Collaboration, editor -Chichester, UK: John Wiley & Sons, Ltd,Palazzuoli A, Ruocco G, Pellegrini M, de Gori C, Del Castillo G, Nuti R et al. Te role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Terapeutics and Clinical Risk Management. 2014,10:641–50. DOI: 10.2147/TCRM.S61551Palazzuoli A, Ruocco G, Pellegrini M, de Gori C, Del Castillo G, Nuti R et al. Te role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Terapeutics and Clinical Risk Management. 2014,10:641–50. DOI: 10.2147/TCRM.S61551Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E et al. Te use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Journal of the American College of Cardiology. 2000,35(7):1737–44. DOI: 10.1016/S0735-1097(00)00613-6Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E et al. Te use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. Journal of the American College of Cardiology. 2000,35(7):1737–44. DOI: 10.1016/S0735-1097(00)00613-6Kotecha D, Ngo K, Walters JAE, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials. American Heart Journal. 2011,161(5):822- 831.e2. DOI: 10.1016/j.ahj.2011.02.013Kotecha D, Ngo K, Walters JAE, Manzano L, Palazzuoli A, Flather MD. Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials. American Heart Journal. 2011,161(5):822- 831.e2. DOI: 10.1016/j.ahj.2011.02.013Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H et al. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients with Symptomatic Heart Failure and Anemia. Circulation. 2008,117(4):526– 35. DOI: 10.1161/CIRCULATIONAHA.107.698514Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H et al. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients with Symptomatic Heart Failure and Anemia. Circulation. 2008,117(4):526– 35. DOI: 10.1161/CIRCULATIONAHA.107.698514Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine. 2013,368(13):1210–9. DOI: 10.1056/NEJMoa1214865Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine. 2013,368(13):1210–9. DOI: 10.1056/NEJMoa1214865

The authors declare that there are no conflicts of interest present.